Detail akcie Biogened online

Business Summary: Biogened SA is a Poland-based company active in the healthcare sector. The Company is engaged in production and distribution of generic pharmaceuticals in psychiatry, neurology and oncology, as well as development, production and distribution of dermocosmetics and diet supplements. The Company’s product portfolio includes: Polmantis and SST Salvia Stimulating Tablets (pharmaceuticals), Dermedic, Ellexir, Herba Botanic and Novoscabin (dermocosmetics), and Fibers, Prolady, Futimal and Dermedic Caps (diet supplemenst). As of March 31, 2012, Life Science Technologies NV held an 80.92% stake in the capital.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, BIOGENED SA revenues increased 17% to PLN81.7M. Net income decreased 6% to PLN3.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was offset by Selling/General/Admin Expense increase of 27% to PLN37.5M (expense), Other Operating Expense increase from PLN521K to PLN2.8M (expense).